Ross Norman, CEO of Metals Daily, joins Yahoo Finance’s Akiko Fujita to discuss gold prices hitting a new record Monday, along with his outlook on silver.
from Yahoo Finance https://ift.tt/30Q2aYp
-
Gold settles at highest level ever
-
Why I would buy Coles and these ASX dividend shares today
Fortunately, in this low interest rate environment, there are a good number of ASX shares paying investors handsome dividends.
Here are three ASX dividend shares that I think income investors should buy right now to beat low rates:
Coles Group Ltd (ASX: COL)
The first ASX dividend share to consider buying is this supermarket operator. I think Coles is well-positioned to grow its dividend at a consistently solid rate over the next decade. This is because of its positive growth outlook thanks to food inflation, its refreshed strategy, defensive earnings, and expansion opportunities. Based on the current Coles share price, I estimate that it offers a fully franked ~3.5% FY 2021 dividend.
Rural Funds Group (ASX: RFF)
A second dividend share to buy today is Rural Funds. It is a leading agriculture-focused property company with a collection of quality assets throughout Australia. I’m a big fan of Rural Funds due to its long term tenancies which have been structured to allow the company to consistently increase its distribution at a solid rate each year. For example, the earnings visibility this provides means the company has already provided its distribution guidance for FY 2021. It plans to pay shareholders a 11.28 cents per share distribution. Based on the current Rural Funds share price, this equates to a 5.6% yield.
Vanguard Australian Shares High Yield ETF (ASX: VHY)
A final option to consider is a dividend-focused exchange traded fund. As its name implies, the Vanguard Australian Shares High Yield ETF has a focus on high yield dividend shares. It provides investors with exposure to 62 of the highest yielding shares on the ASX through just a single investment. This includes the likes of Coles, the big four banks, and high-yielding miners and telcos. At present I estimate that its units offer a FY 2021 dividend yield of at least 4.4%.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
- Is it too late to buy the outperforming Woolworths share price and Coles share price?
- Coles launches new collectables! Is the Coles share price a buy?
- These shares were the ASX 200’s biggest losers last week
- ASX 200 Weekly Wrap: ASX has week of high volatility
- Beat low interest rates on savings accounts with these ASX dividend shares
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended RURALFUNDS STAPLED. The Motley Fool Australia owns shares of COLESGROUP DEF SET. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why I would buy Coles and these ASX dividend shares today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/30T6Pc1
-
Cantor Fitzgerald Raises Aphria Target: ‘Our Top Pick Among Canadian LPs’
Aphria Inc. (NASDAQ: APHA) shares traded higher by 9.2% on Monday ahead of the company's fiscal fourth-quarter results expected out on Wednesday.One Wall Street analyst raised his price target for the stock on Monday ahead of the big report.The AnalystCantor Fitzgerald analyst Pablo Zuanic reiterated his Overweight rating for Aphria and raised his price target from CA$10.50 (US$7.84) to CA$11 (US$8.21).The ThesisAphria continues to be Zuanic's top stock pick among Canadian cannabis producers. He said the company is gaining recreational market share in Canada and will likely beat consensus fourth-quarter sales estimates by roughly $2.24 million.Zuanic is also projecting 25% sequential recreational cannabis sales growth compared to just 20% sequential sales growth for the overall recreational market."We think LPs like APHA, with positive EBITDA, consistent domestic rec/med market share gains, and which are sensibly building businesses overseas (MJ reg issues notwithstanding, we should remember 95% of the world's population lives outside NA, and we still think MJ deregulation will be a global phenomenon), will outperform," Zuanic wrote on Monday.Unfortunately, Aphria investors should keep their expectations muted when it comes to profitability in the fourth quarter, Zuanic added. He said COVID-19 operating disruptions during the quarter likely weighed on cannabis EBITDA margins.In addition, Zuanic is calling for cash burn to improve sequentially from C$91 million in the third quarter to just C$34 million in the fourth quarter. Zuanic is also projecting net cash of C$128 million.In the longer-term Zuanic says Aphria should benefit from the Canadian cannabis market expanding from $1.6 billion in 2019 to $6.2 billion by 2024. Cantor is also projecting the US cannabis market will grow from $12 billion in 2019 to $31 billion by 2024.Benzinga's TakeGiven all the uncertainty that remains in the cannabis space in the near-term, it may be wise for cannabis bulls to take a diversified approach to investing.Consider buying a basket of Canadian legal producers like Aphria as well as US multi-state operators that have high-quality balance sheets and leading market shares.Related Links: Stifel Upgrades Aphria: 'Fundamental Performance Will Drive A Re-Rating' What A Biden Presidency Would Mean For Cannabis StocksLatest Ratings for APHA DateFirmActionFromTo Jul 2020Cantor FitzgeraldMaintainsOverweight Jul 2020StifelUpgradesHoldBuy May 2020Cantor FitzgeraldMaintainsOverweight View More Analyst Ratings for APHA View the Latest Analyst Ratings See more from Benzinga * Here's How Much Investing ,000 In The 2018 Aphria Listing Would Be Worth Today * Canopy Growth Analyst Sees Increasing Cannabis Market Share, Little Stock Upside(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
from Yahoo Finance https://ift.tt/30SIza3
-
HP Enterprise CEO on his recovery from COVID-19
Yahoo Finance’s Brian Sozzi sat down with Antonio Neri, Hewlett Packard Enterprise CEO, to discuss his recent recovery from COVID-19 and more. Sozzi shares the details on The First Trade.from Yahoo Finance https://ift.tt/3303cnm
-
Alaska Air Group, Inc. (NYSE:ALK) Just Reported And Analysts Have Been Cutting Their Estimates
Alaska Air Group, Inc. (NYSE:ALK) just released its latest quarterly results and things are looking bullish. The…
from Yahoo Finance https://ift.tt/2OX7yDx
-
Coronavirus update: Moderna starts next vaccine phase as crisis grows for FL, CA
Florida and California entrenched their status as epicenters of the U.S.’s coronavirus crisis, with both states hammered by rising COVID-19 cases that exceed New York, formerly the domestic leader in infections.
from Yahoo Finance https://ift.tt/3026FQA
-
You can buy a (tiny) home on Amazon
Amazon sells tiny homes, but some assembly may be required.from Yahoo Finance https://ift.tt/3313hYc
-
Read This Before Selling Immunomedics, Inc. (NASDAQ:IMMU) Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are…
from Yahoo Finance https://ift.tt/3jGYHEe
-
Why Opko Health’s Stock Is Trading Higher Today
Opko Health Inc. (NASDAQ: OPK) shares are trading higher on Monday. The stock has surged recently after it was announced the company will be involved in NFL coronavirus testing.Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland.Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.Opko Health shares were up 7.64% at $5.70 during the time of publication on Monday. The stock has a 52-week range between $6.47 and $1.12.See more from Benzinga * Facebook Reschedules Q2 Results To July 30 * Why Global Eagle Entertainment's Stock Is Trading Higher Today * Why AMAG's Stock Is Moving Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
from Yahoo Finance https://ift.tt/39uLaLm